Details for Patent: 8,481,078

Which drugs does patent 8,481,078 protect, and when does it expire?

Patent 8,481,078 protects FENOGLIDE and is included in one NDA.

This patent has twenty-nine patent family members in eleven countries.

Summary for Patent: 8,481,078

Title:	Solid dosage form comprising a fibrate
Abstract:	The invention provides stable, solid dosage forms and pharmaceutical compositions in particulate form comprising a fibrate, for example fenofibrate, dissolved in an non-aqueous vehicle in order to ensure improved bioavailability of the active ingredient upon oral administration relative to known fibrate formulations.
Inventor(s):	Holm; Per (Vanlose, DK), Norling; Tomas (Lyngby, DK)
Assignee:	Veloxis Pharmaceuticals A/S (Horsholm, DK)
Application Number:	13/315,030
Patent Claim Types: see list of patent claims	Composition; Dosage form; Formulation; Use;

Drugs Protected by US Patent 8,481,078

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Salix	FENOGLIDE	fenofibrate	TABLET;ORAL	022118-001	Aug 10, 2007	AB	RX	Yes	No			Y			USE OF FENOFIBRATE FOR REDUCING ELEVATED TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES
Salix	FENOGLIDE	fenofibrate	TABLET;ORAL	022118-002	Aug 10, 2007	AB	RX	Yes	Yes			Y			USE OF FENOFIBRATE FOR REDUCING ELEVATED TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES

International Family Members for US Patent 8,481,078

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2004279661
Australia	2009201881
Brazil	PI0415121
Canada	2540984
Canada	2541382
Canada	2582403
Canada	2582405